Belite Bio (BLTE) Non Operating Income (2022 - 2026)
Belite Bio's (BLTE) quarterly Non Operating Income came in at $5.7 million in Q1 2026, up 363.39% year-on-year from $1.2 million in Q1 2025, and down 99.79% quarter-over-quarter from $2.8 billion in Q4 2025.
Belite Bio (BLTE) Non Operating Income (2022 - 2026) Analysis & Trends
Belite Bio's Non Operating Income history runs 5 years deep, the most recent figure standing at $5.7 million for Q1 2026.
- On a quarterly basis, Non Operating Income rose 363.39% year-over-year to $5.7 million in Q1 2026; TTM through Mar 2026 was $5.4 billion, a 57.9% increase from a year earlier, with the FY2025 full-year figure at $6.6 million, up 71.0% from the prior year.
- Non Operating Income declined to $5.7 million in Q1 2026 per BLTE's latest filing, from $2.8 billion in the prior quarter.
- Across five years, Non Operating Income topped out at $2.8 billion in Q4 2025 and bottomed at -$8.0 million in Q1 2023.
- The 5-year median for Non Operating Income is $126.0 million (2022), against an average of $595.5 million.
- Across the five-year window, Non Operating Income plunged 99.98% in 2023 and soared 3929529.63% in 2024, its largest moves.
- Year by year, Non Operating Income stood at -$62000.0 in 2022, then surged by 41.94% to -$36000.0 in 2023, then jumped by 3769544.44% to $1.4 billion in 2024, then soared by 102.87% to $2.8 billion in 2025, then plunged by 99.79% to $5.7 million in 2026.
- Per Business Quant, the three latest BLTE Non Operating Income figures stand at $5.7 million (Q1 2026), $2.8 billion (Q4 2025), and $1.3 billion (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -9.22 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 444,000.00 |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 188.30 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | 5.75 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -8.59 Mn |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn | -46.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.75 Mn |
| Dec 31, 2025 | 2.75 Bn |
| Sep 30, 2025 | 1.33 Bn |
| Jun 30, 2025 | 1.28 Bn |
| Mar 31, 2025 | 1.24 Mn |
| Dec 31, 2024 | 1.36 Bn |
| Sep 30, 2024 | 1.06 Bn |
| Jun 30, 2024 | 977.00 Mn |
| Mar 31, 2024 | 463.00 Mn |
| Dec 31, 2023 | -36,000.00 |
| Sep 30, 2023 | 27,000.00 |
| Jun 30, 2023 | 62.00 Mn |
| Mar 31, 2023 | -8.00 Mn |
| Dec 31, 2022 | -62,000.00 |
| Sep 30, 2022 | 137.00 Mn |
| Jun 30, 2022 | 115.00 Mn |